Programmable small molecules, precise transcriptional control

Platform

Our bifunctional editors can be built iteratively and rapidly using modular library synthesis

Each molecule is profiled transcriptome wide, surfacing on and off target biology

Data of unparalleled richness and relevance for rapid optimisation and early derisking

Targeted transcriptional editors are tools with extraordinary potential but massive delivery challenges

Lexicon is building a platform for transcriptional editing using small molecules that can go anywhere in the human body

Modular chemistry for rapid library synthesis

High throughput transcriptome-scale profiling

Unlock insight at scale for accelerated discovery and reduced risk

Lexicon’s discovery engine is built to turn high-throughput experiments into actionable decisions

Cloud native QC, analysis, scoring, and signature comparison, linked directly to chemical structure

Rapid library iteration is coupled to a massive and growing dataset of transcriptional data

Pipeline

We have already identified the first activators of a regenerative stem cell pathway, repressors of an undruggable transcription factor, and best-in-class molecules acting on a validated oncology pathway with an entirely novel mechanism.

Delivering transcriptional editing to areas of high unmet need:

  • Oncology

    • Metastatic castration resistant prostate cancer

  • Regenerative medicine

    • Heart failure with reduced ejection fraction

  • Immunology

    • Crohn’s disease and IBD

Team

Alfie Brennan, PhD

Founder

Prior to founding Lexicon Bio, Alfie was the cofounding CSO of Evariste, where he led the build out of the platform and the pipeline, including the discovery of PKMYT1 preclinical candidates. He has worked across multiple epigenetic targets and novel modalities, including degraders of BCL6, RIPK1, and MDM2.

Andy Crew, PhD

Scientific Advisor

The first employee and former CTO of pioneering protein degradation company Arvinas, Andy is a foremost authority in bifunctional molecules. He assembled and led the team that unlocked the secrets of oral bioavailability and blood-brain barrier penetration for bifunctional proximity molecules. He has over 30 years of experience leading teams in pharma & biotech and supporting successful IPOs/exits.

Jean-Christophe Harmange, PhD

Scientific Advisor

Jean-Christophe is a biotech executive with over 30 years of experience in the industry. He is currently the SVP of Drug Discovery at Psithera and has previously worked as the CSO of Triana Biomedicines and Director of Drug Discovery at Constellation Pharmaceuticals. He has deep experience working with epigenetic targets and novel modalities.